Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms-Reference-Cited by-同舟云学术

Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms

Published:2016-03 Issue:3 Volume:38 Page:431-444
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Sharma Roopali,Park Tae Eun,Moy Stanley

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference41 articles.

1. Centers for Disease Control and Prevention (CDC). Antibiotic resistance treats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed September 6, 2015.

2. Bench-to-bedside review: the role of beta-lactamases in antibiotic-resistant Gram-negative infections;Bush;Crit Care,2010

3. Updated functional classification of β-lactamases;Bush;Antimicrob Agents Chemother,2010

4. Extended-spectrum β-lactamases: a clinical update;Paterson;Clin Microbiol Rev,2005

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of an effective meropenem/KPC-2 inhibitor combination to combat infections caused by carbapenem-resistant Klebsiella pneumoniae;International Journal of Antimicrobial Agents;2024-09

2. Resistance to ceftazidime–avibactam and other new β-lactams in Pseudomonas aeruginosa clinical isolates: a multi-center surveillance study;Microbiology Spectrum;2024-08-06

3. Mecanismos moleculares y epidemiología de la resistencia a ceftazidima-avibactam: un análisis integral;Acta Pediátrica de México;2024-07-25

4. Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent Klebsiella pneumoniae;Emerging Microbes & Infections;2024-06-12

5. Multi-resistant organisms in burn patients: an end or a new beginning;Burns;2024-06